"10.1371_journal.pone.0112268","plos one","2014-11-13T00:00:00Z","Jenny A Greig; Hui Peng; Jason Ohlstein; C Angelica Medina-Jaszek; Omua Ahonkhai; Anne Mentzinger; Rebecca L Grant; Soumitra Roy; Shu-Jen Chen; Peter Bell; Anna P Tretiakova; James M Wilson","Gene Therapy Program, Department of Pathology and Laboratory Medicine, Division of Transfusion Medicine, University of Pennsylvania, TRL Suite 2000, 125 South 31st Street, Philadelphia, PA, 19104, United States of America","Conceived and designed the experiments: JAG APT JMW. Performed the experiments: JAG HP JO CAM-J OA AM SC PB. Analyzed the data: JAG PB JMW. Contributed reagents/materials/analysis tools: RLG SR SC PB APT. Wrote the paper: JAG APT JMW.","J.M. Wilson is an advisor to ReGenX Biosciences and Dimension Therapeutics, and is a founder of, holds equity in, and receives grants from ReGenX Biosciences and Dimension Therapeutics; in addition, he is a consultant to several biopharmaceutical companies and is an inventor on patents licensed to various biopharmaceutical companies. Numerous patents describing the isolation of various AAVs and their use in gene therapy have originated from the Gene Therapy Program. Several patents and applications describe methods of producing AAV vectors. Some patents have issued, and some are under prosecution. Our portfolio relating to AAV vectors spans over 200 patents and applications worldwide. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials. All other authors declare no competing interests.","2014","11","Jenny A Greig","JAG",12,FALSE,3,8,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
